Cellular senescence mediates fibrotic pulmonary disease
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index; 18 of the 31 sources its claims cite were checked for support.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by interstitial remodelling, leading to compromised lung function. Cellular senescence markers are detectable within IPF lung tissue and senescent cell deletion rejuvenates pulmonary health in aged mice. Whether and how senescent cells regulate IPF or if their removal may be an efficacious intervention strategy is unknown. Here we demonstrate elevated abundance of senescence biomarkers in IPF lung, with p16 expression increasing with disease severity. We show that the secretome of senescent fibroblasts, which are selectively killed by a senolytic cocktail, dasatinib plus quercetin (DQ), is fibrogenic. Leveraging the bleomycin-injury IPF model, we demonstrate that early-intervention suicide-gene-mediated senescent cell ablation improves pulmonary function and physical health, although lung fibrosis is visibly unaltered. DQ treatment replicates benefits of transgenic clearance. Thus, our findings establish that fibrotic lung disease is mediated, in part, by senescent cells, which can be targeted to improve health and function.
Overview
CoChat Summary
## TL;DR
This study links cellular senescence to idiopathic pulmonary fibrosis (IPF) by showing that senescence markers rise with disease severity in human lung tissue and that senescent fibroblast secretions are profibrotic. In a bleomycin mouse model, clearing senescent cells improved lung function and physical health, and dasatinib plus quercetin (DQ) reproduced the benefits of transgenic senescent-cell ablation.
## Key findings
- In human IPF lung samples, CDKN2A (p16) was significantly upregulated and increased with disease severity; higher pulmonary p16 expression correlated with reduced FVC, diffusion capacity, and SF-12 physical component score.
- In IPF tissue, p16-positive epithelial cells and fibroblasts were found in fibroblastic foci and honeycomb lung, and TAF-positive cells / γH2A.X foci were significantly increased relative to controls.
- In the bleomycin mouse model, lung injury increased whole-lung p16 expression by threefold, and SASP-related transcripts including Mcp1, Il6, Mmp12, Col1a1, and Tgfβ rose after bleomycin exposure.
- Senescent fibroblast conditioned medium was fibrogenic in vitro: it increased αSMA positivity to 62% vs 21% with control conditioned medium, increased traction forces, and induced fibrosis genes such as ACTA2, COL1A1, COL1A2, and FN1.
- In mice, senescent-cell clearance improved pulmonary/physical outcomes: Penh rose about twofold after bleomycin and was diminished by AP or DQ; lung compliance fell by 40% in vehicle-treated bleomycin mice but only 15% with AP or DQ; body weight loss averaged 3.6 g with vehicle vs about 1.6 g with AP/DQ; treadmill distance to exhaustion was >37% further with AP/DQ than vehicle.
- The paper states that histological fibrosis reductions did not reach statistical significance, despite functional benefits.
## Methods
- Human data came from LTRC control and IPF lung tissue samples, including microarray and RNA-seq datasets; the paper reports IPF n=27 and control n=10 for p16 immunohistochemistry, and transcriptome analyses stratified by FVC severity.
- The mouse study used male Ink-Attac mice given aerosolized intratracheal bleomycin (2 U/kg) or PBS, then randomized to AP20187, dasatinib plus quercetin (DQ), or vehicle at either an early prevention timepoint or a later treatment timepoint.
- Analyses included FACS of lung fibroblasts, epithelial cells, and endothelial cells, immunohistochemistry / immunofluorescence, conditioned-medium assays in IMR90 fibroblasts, traction force microscopy, RT-PCR, and statistical modeling with regression and multiple-comparison correction.
## Limitations
- The paper states that the bleomycin model spontaneously resolves, with resolution varying by factors such as genetic background and microbiome, which limits interpretation of late-stage effects.
- The authors state that they could not disentangle senescence-dependent from senescence-independent events governing fibrosis resolution.
- Lung fibrosis histology did not improve significantly after senescent-cell clearance, despite functional gains; the paper itself notes this may reflect the short time course and heterogeneity of the bleomycin model.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
13 Valid · 0 Not valid · 8 Not checked · 94 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Through secretion of the senescence-associated secretory phenotype (SASP), a broad repertoire of cytokines, chemokines, matrix remodelling proteases and growth factors, senescent cells paracrinely promote proliferation and tissue deterioration8.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
In “Senescence is a multi-step evolving process” (page unavailable), the paper says SASP-mediated paracrine signalling affects cell proliferation. In “Senescence in ageing and age-related disease” (page unavailable), it says SASP components are thought to promote proliferation of neoplastic cells and may intensify age-related tissue deterioration. The citing sentence presents those qualified effects as established and general. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cellular senescence is an evolutionarily conserved state of stable replicative arrest induced by pro-ageing stressors also implicated in IPF pathogenesis, including telomere attrition, oxidative stress, DNA damage and proteome instability.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
The Abstract and 'Senescence is a multi-step evolving process' describe growth arrest, including a transition to stable cell-cycle arrest. 'Causes and effector pathways of senescence' identifies telomere erosion, DNA lesions, reactive oxygen species and proteotoxic stress as senescence-related stressors. The cited passages do not establish that senescence is evolutionarily conserved or that these stressors are implicated in IPF pathogenesis; the paper also distinguishes replicative senescence from other forms of senescence. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > Senescent cell retention impairs fibrosis resolution Taken together, our in vivo results strongly support the hypothesis that elimination of senescent cells improves fibrotic pulmonary disease when treatment is initiated at the onset of pathogenesis. We next sought to test the clinically important question of whether senescent cell clearance provides comparable benefit when initiated at a timepoint when pathology has fully developed. Ink-Attac mice contained a strong senescent signature in lung fibroblasts and epithelial cells 2 weeks post-bleomycin challenge (Fig. 2), a timepoint of well-established fibrotic remodelling in the lung15. Accordingly, we administered a single dose of bleomycin or PBS through aerosolized intratracheal administration to Ink-Attac mice. Two weeks post challenge, we randomized bleomycin-exposed mice to AP, DQ or vehicle treatment groups based on change in body weight and non-invasively measured airway resistance (Penh). Mice were treated for 2 weeks and were killed 4 weeks following bleomycin or PBS exposure (Fig. 5a). Body weight monitoring revealed that, similar to our previous experiments (Fig. 4f), mice that received bleomycin lost substantial body mass, relative to mice that received PBS. Upon treatment initiation on day 14, mean body weight of mice treated with AP plateaued, while vehicle-treated, bleomycin-exposed counterparts continued to lose weight (Fig. 5a), suggestive of physical benefit afforded by senescent cell clearance, even when treatment is initiated in later-stage disease. Spontaneous resolution is an inherent limitation of the bleomycin IPF model, with the rate and variability of bleomycin-induced pathology resolution dependent on complex factors, including genetic background and the microbiome3839. Indeed, both endpoint compliance (Supplementary Fig. 6) and comparison of Penh airway resistance at endpoint (4 weeks post challenge) to measures taken at the treatment randomization timepoint (2 weeks post challenge) revealed appreciable, albeit variable, improvement in all bleomycin-exposed groups, including vehicle-treated mice, with AP-treated mice showing greatest improvement (Fig. 5b). Thus, in our hands, the 3–4-week-period following a single bleomycin exposure represents a pivotal window of natural resolution (Figs 4 and 5a,b). Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3. As we were unable to disentangle senescence-dependent and -independent events governing resolution, we queried whether p16 expression, a measure of senescent burden, was associated with indicators of disease persistence. Impaired lung function, as measured by endpoint airway resistance (Penh) (Fig. 5c) and airway compliance (Fig. 5d), correlated significantly with p16 transcript abundance. This finding is consistent with associations drawn in humans, in which increased p16 expression correlated significantly with reduced FVC, pulmonary diffusion capacity and physical function (Supplementary Fig. 1). Similarly, in bleomycin-exposed mice, expression of the inflammatory and fibrogenic SASP factors Mcp1 (Fig. 5e), Pai1 (Fig. 5f), Mmp10 (Fig. 5g) and Col1a1 (Fig. 5h) robustly correlated with p16 transcriptional activation. These results further support the notion that the presence and activities of senescent cells may dictate resolution capacity following bleomycin-induced pathology.
What the sources say
- Supportedcites [3] Hecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci. Transl. Med. 6, 231ra247 (2014). source
The Introduction states that aged mice have impaired fibrosis resolution associated with senescent, apoptosis-resistant myofibroblasts. The Results identify bleomycin as the lung-injury model and report accumulation of senescent myofibroblasts in aged mice with persistent fibrosis. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation.”
§ Cellular senescence mediates fibrotic pulmonary disease > Methods > Cell culture For experiments employing radiation-induced senescence, IMR90 (passages 5–7; ATCC, catalogue number CCL-186) and primary human fibroblasts (passages 3–6) were exposed to 10 Gy radiation or sham conditions using a RS2000 X-Ray Irradiator (RAD Source Technologies, Suwanee, GA). Normal bronchial epithelial cells (passages 4–7, Lot 7F3000, Lonza, Walkersville, MD) were exposed to 5 Gy or sham conditions. Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation. For SA-β-gal staining, cells were fixed for 10 min in 2% formaldehyde+0.2% glutaraldehyde in PBS at room temperature. Cells were rinsed with PBS and incubated overnight in SA-β-gal staining solution containing the following: 1 mg ml−1 X-gal, 40 mM citric acid/sodium phosphate buffer pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM sodium chloride and 2 mM magnesium chloride in water. Cells were then rinsed in PBS and stored at 4 °C until imaging. Media applied 20 days post irradiation (or sham) was collected 24 h later and was diluted with NCM to reflect equivalent source cell concentrations. ProcartaPlex immunoassays (Affymetrix eBioscience) were used for CM secretome composition assessment, according to the manufacturer's specifications. Non-irradiated IMR90 cells (passages 5–7) were treated with NCM, NCM+2 ng ml−1 TGFβ, CCM or SASP-CM and applied to downstream analyses as indicated. Primary human fibroblasts collected from human patients were authenticated through αSMA staining. For senolytic treatment, sham and irradiated primary human fibroblasts were treated with indicated concentrations of DQ or navitoclax for 3 days, starting at day 20 post irradiation or sham exposure. Cell viability after drug treatment was measured by ATPLite Kits (PerkinElmer; Waltham, MA) performed according the manufacturer's instructions. Luminescence was read using a multi-scan plate reader (Fisher). For experiments utilizing etoposide-induced senescence, IMR90 human lung fibroblasts (passage 10; ATCC) were treated for 48 h with 20 μM etoposide (Enzo Life Sciences, Farmingdale, NY). Etoposide was removed and replaced with fresh media. Six days after etoposide removal, approximately 60% of IMR90 cells were SA-β-gal positive. Cells were treated for 48 h with 20 μM D+15 μM Q or 10 μM navitoclax (or untreated control) and the percentage of SA-β-gal-positive cells was determined using a C12FDG-based senescence assay described as follows46. Briefly, etoposide-treated senescent IMR90 cells were seeded at a concentration of 5 × 103 cells per well in 96-well plates 24 h before treatment. Following addition of the drugs, the cells were incubated for 48 h under 20% O2 oxygen conditions. For fluorescence analysis of SA-β-gal activity, cells were incubated for 1 h with 100 nM Bafilomycin A1 (Calbiochem, San Diego, CA). Next, 10 μM C12FDG (Setareh Biotech, Eugene, OR) was added to the culture medium and the cells were incubated for 1.5–2 h. Ten minutes before analysis, the DNA intercalating Hoechst dye (2 μg ml−1) was added to the cells. For quantitative analysis of cell number (Hoechst staining) and number of C12FDG-positive senescent cells, a laser-based line scanning confocal imager IN Cell 6000 Analyzer was used. All samples were analysed in duplicate with three to five fields per well.
What the sources say
- Partly supportedcites [32] Baker, D. J. et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016). sourceExperimental — accuracy not yet measured
In “ATTAC clears senescent adipocyte progenitor cells” (page unavailable), the paper identifies cells using p16 expression, other senescence markers, and SAβ-Gal staining. It studies naturally occurring senescent cells, however, and does not support the claim’s 21-day post-radiation condition. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, CM collected from irradiated bronchiolar epithelial cells did not activate a fibrogenic response, as measured by αSMA fibrotic activation of naive IMR90 cells (Supplementary Fig. 2), suggesting that cell-type-specific SASP composition may differentially affect pathological phenotypes within the lung.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > The secretome of senescent fibroblasts is profibrotic
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
61 more claims
Create a free account to see all 115 claims and to verify the 5 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is in agreement with a recent report showing that the removal of senescent cells expressing high levels of p16INK4a can lead to fibrosis in mice101, whereas small-molecule senolytics appear to reduce fibrosis in several mouse tissues22,71,73,75,102.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in a mouse model of idiopathic pulmonary fibrosis (IPF), D + Q treatment improved lung compliance and reduced frailty71.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with IPF accumulate TAFs and senescence markers in lungs that increase with disease severity and activate SASP52.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of various natural flavonoids, including quercetin and fisetin, either alone or in combination with dasatinib, a pan-tyrosine kinase inhibitor, can stimulate senolysis in a variety of contexts in vitro and in vivo199,207–210.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with enhanced paracrine signaling from increased numbers of senescent neighbors and with established features of epithelial aging.23,25,32–35”
From SenCat: Cataloging human cell senescence through multi-omic profiling of multiple senescent primary cell types (2026) · cites this paper as [33]
Experimental — accuracy not yet measured
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Self-citationNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876 · cited 2×
“Attenuation of age-related pathologies and extension of lifespan in chronologically aged mice has been demonstrated using the same transgenic strategy 32–34 , and improvements in lung structure and function in aged mice have recently been demonstrated using a similar suicide-gene strategy 20 .”
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 2×
“An alternative approach to transgenic senescent cell clearance is senolytics 21,22 , which may be a tractable treatment option for humans.”
Self-citationDesmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R.-M., Vijg, J., Van Steeg, H., Dollé, M. E. T., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.11.012 · Cited by 2,045
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Cited by
Items 201–300 of 1,619
Zhao, J., Zhang, L., Lu, A., Han, Y., Colangelo, D., Bukata, C., Scibetta, A., Yousefzadeh, M. J., Li, X., Gurkar, A. U., et al. (2020) · Aging · doi:10.18632/aging.102863 · Cited by 122
Self-citationCecchini, M. J., Hosein, K., Howlett, C. J., JOSEPH, M. G., & Mura, M. (2018) · Respiratory Research · doi:10.1186/s12931-018-0857-1 · Cited by 141
“Based on this finding and on recent literature [32, 33], we specifically looked at senescence as a mechanism considered relevant into the pathogenesis of IPF.”
BackgroundInfluentialAdvances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
Liu, G. Y., Budinger, G. R. S., & Dematte, J. E. (2022) · BMJ · doi:10.1136/bmj-2021-066354 · Cited by 144
“166”
Senotherapeutics: targeting senescence in idiopathic pulmonary fibrosis
Merkt, W., Bueno, M., Mora, A. L., & Lagares, D. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.12.008 · Cited by 119
“Genetic ablation of p16-positive cells results in marked reduction on the expression of pro-fibrotic and pro-inflammatory cytokines, leading to improved lung function and fitness even in the absence of fibrotic reversal [49].”
BackgroundInfluentialIonizing radiation-induced cellular senescence promotes tissue fibrosis after radiotherapy. A review
Nguyen, H. Q., To, N. H., Zadigue, P., Kerbrat, S., De La Taille, A., Le Gouvello, S., & Belkacemi, Y. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.012 · Cited by 120
Del Rey, M. J., Valín, Á., Usategui, A., Ergueta, S., Martín, E., Municio, C., Cañete, J. D., Blanco, F. J., Criado, G., & Pablos, J. L. (2019) · Immunity & Ageing · doi:10.1186/s12979-019-0169-4 · Cited by 119
Senolytic therapy ameliorates renal fibrosis postacute kidney injury by alleviating renal senescence
Li, C., Shen, Y., Huang, L., Liu, C., & Wang, J. (2021) · The FASEB Journal · doi:10.1096/fj.202001855rr · Cited by 119
Meng, J., Li, Y., Wan, C., Sun, Y., Dai, X., Huang, J., Hu, Y. W., Gao, Y., Wu, B., Zhang, Z., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146334 · Cited by 139
“Strategies to eliminate senescent cells have been proven to restore pulmonary compliance, structure, and elasticity, subsequently improving pulmonary function in aging mice (21, 44).”
Erratum: Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.225 · Cited by 128
Belle, J. I., Sen, D., Baer, J. M., Liu, X., Lander, V. E., Ye, J., Sells, B. E., Knolhoff, B. L., Ahmad, F. F., Kang, L., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0428 · Cited by 136
Paramos-de-Carvalho, D., Jacinto, A., & Saúde, L. (2021) · eLife · doi:10.7554/elife.72449 · Cited by 111
“Similarly, in a mouse model of idiopathic pulmonary fibrosis (IPF), a chronic lung disease characterized by decreased lung function due to persistent scarring, senescent epithelial cells and fibroblasts accumulate continuously over time, inducing myofibroblast differentiation and exacerbating the fibrotic response (Sc…”
BackgroundExtracellular Vesicles from Fibroblasts Induce Epithelial-Cell Senescence in Pulmonary Fibrosis
Kadota, T., Yoshioka, Y., Fujita, Y., Araya, J., Minagawa, S., Hara, H., Miyamoto, A., Suzuki, S., Fujimori, S., Kohno, T., et al. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0002oc · Cited by 134
Cellular senescence: Neither irreversible nor reversible
Reimann, M., Lee, S., & Schmitt, C. A. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232136 · Cited by 134
“…disease, COVID-19, or osteo-arthritis (D¨orr et al., 2013; Jeon et al., 2017; Lee et al., 2021; Omori et al., 2020; Reimann et al., 2021; Schafer et al., 2017; Schleich et al., 2020; Schmitt et al., 2002), for instance, are increasingly exploitable by proliferation-related PET imaging and…”
BackgroundKumar, A., Cherian, S. V., Vassallo, R., Yi, E. S., & Ryu, J. H. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.11.023 · Cited by 118
Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic
Galiana, I., Lozano-Torres, B., Sancho, M., Alfonso, M., Bernardos, A., Bisbal, V., Serrano, M., Martínez-Máñez, R., & Orzáez, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.045 · Cited by 115
Han, D., Gong, H., Wei, Y., Xu, Y., Zhou, X., Wang, Z., & Feng, F. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154680 · Cited by 134
Thuan, D. T. B., Zayed, H., Eid, A. H., Abou-Saleh, H., Nasrallah, G. K., Mangoni, A. A., & Pintus, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01985 · Cited by 122
Wu, H., Ma, H., Wang, L., Zhang, H., Lu, L., Xiao, T., Cheng, C., Wang, P., Yang, Y., Wu, M., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.65861 · Cited by 122
“In senescent cells, the lysosomal hydrolase, β-galactosidase, which is called “senescence-related β-galactosidase” is expressed [11].”
BackgroundInfluentialXu, P., Wang, M., Song, W.-M., Wang, Q., Yuan, G.-C., Sudmant, P. H., Zare, H., Tu, Z., Orr, M. E., & Zhang, B. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00507-7 · Cited by 114
“Moreover, the senescent cell types we identified have been associated with human diseases in other studies, such as fibroblasts in idiopathic pulmonary fibrosis [8] and endothelial cells in atherosclerosis [75].”
BackgroundDai, Y., Guo, Y., Tang, W., Chen, D., Xue, L., Chen, Y., Guo, Y., Wei, S., Wu, M., Dai, J., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02501-9 · Cited by 144
“Telomere shortening, DNA damage response (DDR), and cellular senescence are all linked to pulmonary fibrosis [154, 155].”
BackgroundVeith, C., Boots, A. W., Idris, M., van Schooten, F., & van der Vliet, A. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7742 · Cited by 119
“AECs become more prone to undergo apoptosis (212), while fibroblasts and myofibroblasts become more resistant against this process (203).”
BackgroundCell senescence and fibrotic lung diseases
Liu, R.-M., & Liu, G. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.110836 · Cited by 113
Metabolic features and regulation in cell senescence
Kwon, S. M., Hong, S. M., Lee, Y.-K., Min, S., & Yoon, G. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.291 · Cited by 111
“number of studies have described that cellular senescence was also involved in various age-associated diseases, such as atherosclerosis, fibrotic pulmonary disease, hepatic steatosis, osteoarthritis, cancer, and Alzheimer’s disease (5-8), suggesting that cell senescence may causally drive these diseases.”
BackgroundCellular senescence in the lung across the age spectrum
Parikh, P., Wicher, S., Khandalavala, K., Pabelick, C. M., Britt, R. D., & Prakash, Y. S. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00424.2018 · Cited by 112
“In the bleomycin mouse model of pulmonary fibrosis, DNA and oxidative damage and have been noted to induce senescence in multiple cell types, including endothelium, fibroblasts, and epithelium (6, 158).”
BackgroundInfluentialSelf-citationThe Aging Lung and Idiopathic Pulmonary Fibrosis
Gulati, S., & Thannickal, V. J. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.02.008 · Cited by 111
Telomeres, Telomerase and Ageing
Saretzki, G. (2018) · Subcellular Biochemistry · doi:10.1007/978-981-13-2835-0_9 · Cited by 93
Senescent Cells: A Therapeutic Target in Cardiovascular Diseases
Suda, M., Paul, K. H., Minamino, T., Miller, J. D., Lerman, A., Ellison-Hughes, G. M., Tchkonia, T., & Kirkland, J. L. (2023) · Cells · doi:10.3390/cells12091296 · Cited by 112
“In vitro, senescent fibroblasts can secrete profibrotic enzymes [23].”
BackgroundSelf-citationKovacovicova, K., Skolnaja, M., Heinmaa, M., Mistrik, M., Pata, P., Pata, I., Bartek, J., & Vinciguerra, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00459 · Cited by 110
“D+Q previously showed efficacy also in pre-clinical models of fibrotic pulmonary disease (11).”
BackgroundTanner, L., Single, A., Bhongir, R. K. V., Heusel, M., Mohanty, T., Karlsson, C. A. Q., Pan, L., Clausson, C.-M., Bergwik, J., Wang, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36314-5 · Cited by 123
Cellular senescence: a double-edged sword in cancer therapy
Xiao, S., Qin, D., Hou, X., Tian, L., Yu, Y., Zhang, R., Lyu, H., Guo, D. S., Chen, X., Zhou, C., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1189015 · Cited by 143
“According to the report, the senolytic cocktail of D+Q was effective in reducing injury idiopathic pulmonary fibrosis (IPF) and against senescent alveolar epithelial cell types by selectively eliminating senescent cells (91, 92).”
Shih, A., Adelson, R. P., Vashistha, H., Khalili, H., Nayyar, A., Puran, R., Herrera, R., Chatterjee, P. K., Lee, A. T., Truskinovsky, A. M., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02500-3 · Cited by 127
Senescent cells suppress macrophage-mediated corpse removal via upregulation of the CD47-QPCT/L axis
Schloesser, D., Lindenthal, L., Sauer, J., Chung, K.-J., Chavakis, T., Griesser, E., Baskaran, P., Maier-Habelsberger, U., Fundel-Clemens, K., Schlotthauer, I., et al. (2023) · Journal of Cell Biology · doi:10.1083/jcb.202207097 · Cited by 108
“Thus, various pathophysiological scenarios are linked to the accumulation of senescent cells and expression of CD47 (McHugh and Gil, 2018; Palmer et al., 2019; Schafer et al., 2017).”
Progressive Cellular Senescence Mediates Renal Dysfunction in Ischemic Nephropathy
Kim, S. R., Puranik, A. S., Jiang, K., Chen, X., Zhu, X.-Y., Taylor, I., Khodadadi-Jamayran, A., Lerman, A., Hickson, L. J., Childs, B. G., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020091373 · Cited by 106
“The flavonol quercetin combined with the pan-tyrosine kinase inhibitor dasatinib (DQ) have been shown to reduce senescent cell burden in mouse tissues, and to delay, prevent, or alleviate age- and senescence-related conditions.(29,30) Furthermore, in the first clinical trials of this translatable approach,(31,32) DQ a…”
BackgroundSelf-citationMitochondrial Dysfunction in Pulmonary Fibrosis
Rangarajan, S., Bernard, K. F., & Thannickal, V. J. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201705-370aw · Cited by 115
Fibroblast Senescence in Idiopathic Pulmonary Fibrosis
Lin, Y., & Xu, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.593283 · Cited by 115
Targeting senescent cells for a healthier longevity: the roadmap for an era of global aging
Sun, Y., Li, Q., & Kirkland, J. L. (2022) · Life Medicine · doi:10.1093/lifemedi/lnac030 · Cited by 105
Self-citationTripathi, U., Misra, A., Tchkonia, T., & Kirkland, J. L. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111548 · Cited by 104
“…6) improved pulmonary function and reduced pulmonary fibrosis in mice with bleomycin-induced lung damage, a model of idiopathic pulmonary fibrosis [71]; 7) improved physical function and increased median lifespan in old mice [53, 73]; 8) improved cardiac ejection fraction and fractional…”
Self-citationCellular Senescence and Iron Dyshomeostasis in Alzheimer’s Disease
Masaldan, S., Belaidi, A. A., Ayton, S., & Bush, A. I. (2019) · Pharmaceuticals · doi:10.3390/ph12020093 · Cited by 102
“A small (n = 14) first in-human clinical trial of the senolytic cocktail of dasatinib and quercetin in idiopathic pulmonary fibrosis (IPF), a fatal cellular senescence-associated disease [76], provided no conclusive evidence of senescence clearance or reduction in SASP despite achieving its primary endpoints (retentio…”
BackgroundIakovou, E., & Kourti, M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.827900 · Cited by 129
Cellular senescence and radiation-induced pulmonary fibrosis
He, Y., Thummuri, D., Zheng, G., Okunieff, P., Citrin, D. E., Vujaskovic, Z., & Zhou, D. (2019) · Translational Research · doi:10.1016/j.trsl.2019.03.006 · Cited by 103
Ng, B., Cook, S. A., & Schafer, S. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00531-5 · Cited by 102
Cellular senescence and its role in white adipose tissue
Smith, U., Li, Q., Rydén, M., & Spalding, K. L. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00757-x · Cited by 121
Zhang, X., Pearsall, V. M., Carver, C. M., Atkinson, E. J., Clarkson, B. D. S., Grund, E. M., Baez-Faria, M., Pavelko, K. D., Kachergus, J. M., White, T. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33226-8 · Cited by 102
Self-citationTargeting Senescent Cells in Fibrosis: Pathology, Paradox, and Practical Considerations
Schafer, M. J., Haak, A. J., Tschumperlin, D. J., & LeBrasseur, N. K. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0712-x · Cited by 110
Self-citationDeletion of SA β‐Gal+ cells using senolytics improves muscle regeneration in old mice
Dungan, C. M., Murach, K. A., Zdunek, C. J., Tang, Z. J., Nolt, G. L., Brightwell, C. R., Hettinger, Z., Englund, D. A., Liu, Z., Fry, C. S., et al. (2022) · Aging Cell · doi:10.1111/acel.13528 · Cited by 102
“Because senescent cells have been associated with tissue fibrosis in the lung (Citrin et al., 2013; Minagawa et al., 2011; Schafer et al., 2017), total fibrous collagen content, as well as the content of loosely and tightly packed collagen, were assessed using Sirius red staining followed by…”
MethodNovais, E. J., Diekman, B. O., Shapiro, I. M., & Risbud, M. V. (2019) · Matrix Biology · doi:10.1016/j.matbio.2019.02.004 · Cited by 100
The clinical impact and biological mechanisms of skeletal muscle aging
Aversa, Z., Zhang, X., Fielding, R. A., Lanza, I., & LeBrasseur, N. K. (2019) · Bone · doi:10.1016/j.bone.2019.05.021 · Cited by 101
Self-citationCellular senescence as a potential mediator of COVID‐19 severity in the elderly
Nehme, J., Borghesan, M., Mackedenski, S., Bird, T. G., & Demaria, M. (2020) · Aging Cell · doi:10.1111/acel.13237 · Cited by 94
“…for chronic inflammation (Kumar et al., 2014; Tsuji et al., 2010), while TGF-β, PAI-1, and MMPs might contribute to fibrosis (Lomas et al., 2012) and stimulate the expression of fibrotic genes, such as ACTA2, COL1A1, COL1A2, and FN1, in surrounding non-senescent cells (Schafer et al., 2017).”
BackgroundPrinciples of the Molecular and Cellular Mechanisms of Aging
da Silva, P. F. L., & Schumacher, B. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.11.018 · Cited by 100
Zhang, X., Liu, X., Du, Z., Wei, L., Fang, H., Dong, Q., Niu, J., Li, Y., Gao, J., Zhang, M. Q., et al. (2021) · Genome Research · doi:10.1101/gr.275235.121 · Cited by 99
“…premature senescence induced by genotoxic drugs (such as bleomycin, used for anticancer chemotherapy and capable of producing DNA damage) is another type of SIPS different from OIS (Robles and Adami 1998; Bhaumik et al. 2009; Schafer et al. 2017), also employed on BJ fibroblasts in this study.”
BackgroundInfluentialVimentin intermediate filament assembly regulates fibroblast invasion in fibrogenic lung injury
Surolia, R., Li, F. J., Wang, Z., Li, H., Dsouza, K., Thomas, V., Mirov, S., Pérez-Sala, D., Athar, M., Thannickal, V. J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123253 · Cited by 99
Impaired Myofibroblast Dedifferentiation Contributes to Nonresolving Fibrosis in Aging
Kato, K., Logsdon, N. J., Shin, Y.-J., Palumbo, S., Knox, A., Irish, J. D., Rounseville, S. P., Rummel, S. R., Mohamed, M., Ahmad, K., et al. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0092oc · Cited by 113
“Furthermore, recent studies have also suggested that alveolar epithelial cell senescence contributes to IPF pathogenesis (27, 52).”
BackgroundResultStrategies for late phase preclinical and early clinical trials of senolytics
Wissler Gerdes, E. O., Misra, A., Netto, J. M. E., Tchkonia, T., & Kirkland, J. L. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111591 · Cited by 103
“Fisetin induced apoptosis in senescent human umbilical vein endothelial cells (HUVECs) [49].”
Self-citationJin, W., Zhang, W., Tang, H., Wang, P., Zhang, Y., Liu, S., Qiu, J., Chen, H., Wang, L., Wang, R., et al. (2024) · Environment International · doi:10.1016/j.envint.2024.108489 · Cited by 117
Self-citationCellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics
Frey, N., Venturelli, S., Zender, L., & Bitzer, M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.146 · Cited by 97
Cárdenes, N., Álvarez, D., Sellarés, J., Peng, Y., Corey, C., Wecht, S., Nouraie, S. M., Shanker, S., Sembrat, J., Bueno, M., et al. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0970-6 · Cited by 97
Mitochondrial dysfunction contributes to the senescent phenotype of IPF lung fibroblasts
Schuliga, M., Pechkovsky, D. V., Read, J., Waters, D. W., Blokland, K. E. C., Reid, A. T., Hogaboam, C. M., Khalil, N., Burgess, J. K., Prêle, C. M., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13855 · Cited by 97
“The SASP is an important pathological feature of senescence.(6,29) In this study, IPF‐LFs exhibited increased production of cytokines typically associated with the SASP, as well as a markedly pro‐inflammatory gene expression profile.”
BackgroundOrally-active, clinically-translatable senolytics restore α-Klotho in mice and humans
Zhu, Y., Prata, L. G. P. L., Gerdes, E. O. W., Netto, J. M. E., Pirtskhalava, T., Giorgadze, N., Tripathi, U., Inman, C. L., Johnson, K. O., Xue, A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103912 · Cited by 100
Self-citationThe Role of Pathological Aging in Cardiac and Pulmonary Fibrosis
Murtha, L. A., Morten, M., Schuliga, M. J., Mabotuwana, N. S., Hardy, S. A., Waters, D. W., Burgess, J. K., Ngo, D. T., Sverdlov, A. L., Knight, D. A., et al. (2019) · Aging and disease · doi:10.14336/ad.2018.0601 · Cited by 96
“molecules which target senescent cells, and the selective ablation of senescent cells have been demonstrated in transgenic ‘Ink Attac’ mice to attenuate lung fibrosis following bleomycin instillation [28].”
BackgroundMolecular basis of ageing in chronic metabolic diseases
Spinelli, R., Parrillo, L., Longo, M., Florese, P., Desiderio, A., Zatterale, F., Miele, C., Raciti, G. A., & Bèguinot, F. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01255-z · Cited by 110
Watanabe, S., Markov, N. S., Lu, Z., Piseaux Aillon, R., Soberanes, S., Runyan, C. E., Ren, Z., Grant, R. A., Maciel, M., Abdala-Valencia, H., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101100118 · Cited by 96
“Our finding that relief of the ISR is associated with a loss of this transitional cell population in mice therefore provides an alternative explanation for the increase in senescence markers reported in murine models of pulmonary fibrosis and in patients with pulmonary fibrosis (61).”
PGC1α repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state
Caporarello, N., Meridew, J. A., Jones, D. L., Tan, Q., Haak, A. J., Choi, K. M., Manlove, L. J., Prakash, Y. S., Tschumperlin, D. J., & Ligresti, G. (2019) · Thorax · doi:10.1136/thoraxjnl-2019-213064 · Cited by 95
Self-citationBeyond Tumor Suppression: Senescence in Cancer Stemness and Tumor Dormancy
Triana-Martínez, F., Loza, M. I., & Domínguez, E. (2020) · Cells · doi:10.3390/cells9020346 · Cited by 95
Englund, D. A., Zhang, X., Aversa, Z., & LeBrasseur, N. K. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111595 · Cited by 94
Self-citationEarly Vascular Ageing and Cellular Senescence in Chronic Kidney Disease
Dai, L., Qureshi, A. R., Witasp, A., Lindholm, B., & Stenvinkel, P. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.06.015 · Cited by 94
“For instance, navitoclax, targeting the B-cell lymphoma (Bcl-2) family of proteins, is effective as a senolytic in human umbilical vein endothelial and lung fibroblastlike cell strains but not in primary human fat cell progenitors nor primary human lung fibroblasts [24,68].”
BackgroundExtracellular vesicles and aging
Robbins, P. D. (2017) · Stem Cell Investigation · doi:10.21037/sci.2017.12.03 · Cited by 93
“Clearance of senescent cells in versions of this genetic model (INK-ATTAC and 3MR mice) or treating mice with novel senolytics extended healthspan (31,32), restored vascular reactivity (33), stabilized atherosclerotic plaques (34), improved pulmonary function (35), alleviated osteoarthritis (28), improved fatty liver…”
BackgroundSelf-citationMarshall, D. C., Salciccioli, J. D., Shea, B. S., & Akuthota, P. (2018) · European Respiratory Journal · doi:10.1183/13993003.01603-2017 · Cited by 100
Hsp90 inhibitors as senolytic drugs to extend healthy aging
Fuhrmann-Stroissnigg, H., Niedernhofer, L. J., & Robbins, P. D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1475828 · Cited by 92
“Dasatinib (D) and quercetin (Q) [11,117] FOXO-p53, PI3Kδ AKT, reactive oxygen species (ROS), tyrosine kinases, ephrin receptor, serpines (PAI-1, −2) senolytic Yes”
BackgroundSelf-citationSenescent cells and the incidence of age‐related diseases
Katzir, I., Adler, M., Karin, O., Mendelsohn‐Cohen, N., Mayo, A., & Alon, U. (2021) · Aging Cell · doi:10.1111/acel.13314 · Cited by 85
“…senolytic drugs that kill senescent cells (Hickson et al., 2019; Jeon et al., 2017; Justice et al., 2019; Palmer et al., 2019; Pignolo et al., 2020; Schafer et al., 2017b; Short et al., 2019; Xu et al., 2018), and immune therapy that causes T cells to target senescent cells (Amor et al., 2020).”
BackgroundDePianto, D. J., Heiden, J. A. V., Morshead, K. B., Sun, K.-H., Modrusan, Z., Teng, G., Wolters, P. J., & Arron, J. R. (2021) · JCI Insight · doi:10.1172/jci.insight.143626 · Cited by 92
“In preclinical mouse models, uncapping of telomeres in alveolar epithelial type II cells incurs senescence-inducing stress and drives spontaneous pulmonary fibrosis (26, 29).”
Dysfunctional ERG signaling drives pulmonary vascular aging and persistent fibrosis
Caporarello, N., Lee, J., Pham, T. X., Jones, D. L., Guan, J., Link, P. A., Meridew, J. A., Marden, G., Yamashita, T., Osborne, C. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31890-4 · Cited by 95
Self-citationEpigenetic Mechanisms Impacting Aging: A Focus on Histone Levels and Telomeres
Song, S., & Johnson, F. B. (2018) · Genes · doi:10.3390/genes9040201 · Cited by 101
“Other studies have shown similarly that targeted apoptosis of senescent cells can restore fitness, hair density, and renal function [21], inhibit atherosclerosis [22], and ameliorate pulmonary fibrosis [23].”
BackgroundMyofibroblast dedifferentiation proceeds via distinct transcriptomic and phenotypic transitions
Fortier, S. M., Penke, L. R. K., King, D., Pham, T. X., Ligresti, G., & Peters-Golden, M. L. (2021) · JCI Insight · doi:10.1172/jci.insight.144799 · Cited by 101
“It is now recognized that myofibroblasts have multiple potential fates (8, 66-68).”
Self-citationp21 induces a senescence program and skeletal muscle dysfunction
Englund, D. A., Jolliffe, A., Aversa, Z., Zhang, X., Sturmlechner, I., Sakamoto, A. E., Zeidler, J. D., Warner, G. M., McNinch, C., White, T. A., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101652 · Cited by 90
Self-citationIntegrin-mediated adhesions in regulation of cellular senescence
Shin, E.-Y., Park, J.-H., You, S.-T., Lee, C.-S., Won, S.-Y., Park, J.-J., Kim, H.-B., Shim, J., Soung, N.-K., Lee, O.-J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay3909 · Cited by 90
“Cellular senescence in the lung has recently being recognized as causally associated with ARDs including idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease (30, 31).”
BackgroundZhang, C., Zhong, W., Liu, Y., Duan, J., Jiang, N., Yang, H., Ma, S., Jin, L., Hong, J., Zhou, Y., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102765 · Cited by 104
Li, W., Tan, S., Li, X., Sun, T., Li, D., Du, J., Wei, S., Li, Y., & Zhang, B. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.023 · Cited by 102
“For instances, senescent fibroblasts were detected within lung tissue of pulmonary fibrosis, and intervention of SASP from senescent fibroblasts improved pulmonary function and physical health (Schafer et al., 2017).”
BackgroundTripathi, U., Nchioua, R., Prata, L. G. P. L., Zhu, Y., Gerdes, E. O. W., Giorgadze, N., Pirtskhalava, T., Parker, E., Xue, A., Espindola-Netto, J. M., et al. (2021) · Aging · doi:10.18632/aging.203560 · Cited by 88
Self-citationFunctional heterogeneity in senescence
Kirschner, K., Rattanavirotkul, N., Quince, M. F., & Chandra, T. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190109 · Cited by 89
Biomarkers of cellular senescence and risk of death in humans
St. Sauver, J. L., Weston, S. A., Atkinson, E. J., Mc Gree, M. E., Mielke, M. M., White, T. A., Heeren, A. A., Olson, J. E., Rocca, W. A., Palmer, A. K., et al. (2023) · Aging Cell · doi:10.1111/acel.14006 · Cited by 86
“…with advancing age and are enriched in human tissues with disease and/or dysfunction, including skeletal muscle (Englund et al., 2023), lung (Schafer et al., 2017), brain (Neumann et al., 2023), adipose tissue (Choudhery et al., 2014), bone (Farr et al., 2016), and kidney (Barnett et al.,…”
BackgroundSelf-citationThe redox-senescence axis and its therapeutic targeting
Ngoi, N. Y., Liew, A. Q., Chong, S. J. F., Davids, M. S., Clement, M.-V., & Pervaiz, S. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102032 · Cited by 88
Senescence of alveolar epithelial progenitor cells: a critical driver of lung fibrosis
Parimon, T., Chen, P., Stripp, B. R., Liang, J., Jiang, D., Noble, P. W., Parks, W. C., & Yao, C. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00239.2023 · Cited by 110
The aged extracellular matrix and the profibrotic role of senescence-associated secretory phenotype
Mebratu, Y. A., Soni, S., Rosas, L., Rojas, M. M., Horowitz, J. C., & Nho, R. S. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00124.2023 · Cited by 103
Short-term gain, long-term pain: the senescence life cycle and cancer
Chan, A. S. L., & Narita, M. (2019) · Genes & Development · doi:10.1101/gad.320937.118 · Cited by 80
“Association between fibrogenic senescence and chronic tissue damage/inflammation has also been reported in an idiopathic pulmonary fibrosis mouse model (Schafer et al. 2017).”
BackgroundCellular Senescence: The Trojan Horse in Chronic Lung Diseases
Hamsanathan, S., Alder, J. K., Sellares, J., Rojas, M., Gurkar, A. U., & Mora, A. L. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0410tr · Cited by 86
“IPF (87, 109, 121) and the finding that quercetin can reverse their resistance to death ligand–induced apoptosis (120).”
BackgroundInfluentialTargets for protection and mitigation of radiation injury
Khodamoradi, E., Hoseini‐Ghahfarokhi, M., Amini, P., Motevaseli, E., Shabeeb, D., Musa, A. E., Najafi, M., & Farhood, B. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03479-x · Cited by 92
Is exercise a senolytic medicine? A systematic review
Chen, X., Yi, Z., Wong, G. T., Hasan, K. M. M., Kwan, J. S., Ma, A. C., & Chang, R. C. (2021) · Aging Cell · doi:10.1111/acel.13294 · Cited by 88
Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice
Han, M.-M., He, X.-Y., Tang, L., Qi, L., Yang, M.-Y., Wang, Y., Xing, L., Jeong, J.-H., & Jiang, H.-L. (2023) · Science Advances · doi:10.1126/sciadv.adg5358 · Cited by 86
“…suggesting that the expression levels of cell cycle regulators, including Cdkn2a and Cdkn1a , are up-regulated in fibroblasts and epithelial cells in fibrotic lungs, resulting in cell death and the generation of fibrotic factors [MMP-12, monocyte chemoattractant protein-1 (MCP1), and TGF-β] ( 39 ).”
Cellular senescence-mediated exacerbation of Duchenne muscular dystrophy
Sugihara, H., Teramoto, N., Nakamura, K., Shiga, T., Shirakawa, T., Matsuo, M., Ogasawara, M., Nishino, I., Matsuwaki, T., Nishihara, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73315-6 · Cited by 85
“The respiratory function of DMD rats and their age-matched WT rats (from 6 to 10 months of age) was measured with a FinePoint Pulmonary Function Testing (PFT) system (Primetech, Tokyo, Japan).”
MethodInfluentialT Cell Immunosenescence in Aging, Obesity, and Cardiovascular Disease
Shirakawa, K., & Sano, M. (2021) · Cells · doi:10.3390/cells10092435 · Cited by 97
Cellular Senescence: Mechanisms and Therapeutic Potential
Liao, Z., Yeo, H. L., Wong, S. W., & Zhao, Y. X. (2021) · Biomedicines · doi:10.3390/biomedicines9121769 · Cited by 92
“An attest to the cruciality of the tight regulation and removal of senescent cells for any beneficial gain is shown in idiopathic pulmonary fibrosis (IPF), a chronic lung disease, in which senescence plays a contradictory role in the fibrosis response [95].”
BackgroundPotential Regulators of the Senescence-Associated Secretory Phenotype During Senescence and Aging
Han, X., Lei, Q., Xie, J., Liu, H., Li, J., Zhang, X., Zhang, T., & Gou, X. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac097 · Cited by 110
Tsuji, S., Minami, S., Hashimoto, R., Konishi, Y., Suzuki, T., Kondo, T., Sasai, M., Torii, S., Ono, C., Shichinohe, S., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00170-7 · Cited by 84
Hyperoxia-Induced Cellular Senescence in Fetal Airway Smooth Muscle Cells
Parikh, P., Britt, R. D., Manlove, L. J., Wicher, S. A., Roesler, A., Ravix, J., Teske, J., Thompson, M. A., Sieck, G. C., Kirkland, J. L., et al. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0176oc · Cited by 84
“Effect of D1Q Treatment on Reversal of Senescence Markers, ECM, and SASP Profile Dose–response studies using SA b-Gal staining as an endpoint demonstrated trends toward reduction with doses of quercetin of greater than 500 nM (Figure E1B) and several doses of dasatinib (Figure E1A).”
BackgroundMethodInfluentialSelf-citationWang, S., Wang, X., Cheng, Y., Ouyang, W., Sang, X., Liu, J., Su, Y., Liu, Y., Li, C., Yang, L., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/3632169 · Cited by 96
“D+Q treatment can clear SNCs mediated by bleomycin and downregulate p16 and the SASP components MCP-1, IL-6, MMP-2, and TGF-β [55].”
BackgroundCellular Senescence and the Kidney: Potential Therapeutic Targets and Tools
Knoppert, S. N., Valentijn, F. A., Nguyen, T. Q., Goldschmeding, R., & Falke, L. L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00770 · Cited by 83
Deryabin, P. I., Griukova, A., Nikolsky, N. N., & Borodkina, A. V. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03374-0 · Cited by 96
“For now, clearance of senescent cells is described to be beneficial for treatment of various age‐related conditions, including frailty [25, 37, 38], atherosclerosis [37], osteoporosis [39], osteoarthritis [40], and idiopathic pulmonary fibrosis [41].”
BackgroundChiang, G. C., & Parimon, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032405 · Cited by 101
“Cellular senescence is a hallmark of aging processes and is well-described in lung fibrosis, primarily IPF, as one of the vital cellular mechanisms [32,92].”
BackgroundCurrent senolytics: Mode of action, efficacy and limitations, and their future
Rad, A. N., & Grillari, J. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111888 · Cited by 83
“…Alzheimer ’ s (Zhang et al., 2019), osteoarthritis (Coryell et al., 2021), osteoporosis (Farr et al., 2017), idiopathic pulmonary fibrosis (Schafer et al., 2017), hepatic steatosis (Ogrodnik et al., 2017), and Trisomy 21 (Meharena et al., 2022) in which their selective ablation exhibited…”
BackgroundReactive gliosis in traumatic brain injury: a comprehensive review
Amlerova, Z., Chmelová, M., Anděrová, M., & Vargová, L. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1335849 · Cited by 93
Metadata
- Authors
- Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., Mazula, D. L., Brooks, R. W., Fuhrmann-Stroissnigg, H., Pirtskhalava, T., Prakash, Y. S., Tchkonia, T., Robbins, P. D., Aubry, M. C., Passos, J. F., Kirkland, J. L., Tschumperlin, D. J., Kita, H., & LeBrasseur, N. K.
- Affiliations
- Mayo Clinic (US)
- Newcastle University (GB)
- Scripps Research Institute (US)
- Corresponding author
- LeBrasseur, Nathan K.
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-23
- Volume
- 8
- Issue
- 1
- Pages
- 14532-14532
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5331226
- OpenAlex
- W2591114726
- Cited by
- 1,613
- References
- 52
- Citations by year
- 2026: 195 · 2025: 205 · 2024: 193 · 2023: 193 · 2022: 192 · 2021: 181 · 2020: 176 · 2019: 128 · 2018: 107 · 2017: 42
- FWCI
- 91.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Mayo Clinic (UL1-TR000135)
- Glenn Foundation for Medical Research
- Louisiana Transportation Research Center
- Georgia Clinical and Translational Science Alliance (UL1 TR000135)
- Noaber Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health (UL1TR000135, 2r01hl092961-13)
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council (BB/K017314/1, BB/H022384/1)
- National Institute on Aging (R01AG053832, R01AG013925, R37AG013925)
- National Heart, Lung, and Blood Institute (R01-HL-092961)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- cellular senescence, idiopathic pulmonary fibrosis, senolytics, senescence-associated secretory phenotype, senescent fibroblasts, p16, bleomycin-induced lung injury, interstitial pulmonary fibrosis, suicide gene therapy, lung function
- MeSH terms
- Animals, Bleomycin, Fibroblasts, Humans, Lung, Male, Biomarkers, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Proteome, Mice, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.